Published in JAMA Dermatol on February 01, 2013
Cutaneous manifestations of hepatitis C in the era of new antiviral agents. World J Hepatol (2015) 0.85
Short and long-term effects of telaprevir on kidney function in patients with hepatitis C virus infection: a retrospective cohort study. PLoS One (2015) 0.80
Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C. J Dermatol Case Rep (2014) 0.79
Antiviral drug allergy. Immunol Allergy Clin North Am (2014) 0.76
ISMP Adverse Drug Reactions. Hosp Pharm (2013) 0.75
Cutaneous Eruption due to Telaprevir. Case Rep Dermatol (2015) 0.75
Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients. Drugs R D (2015) 0.75
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol (2007) 2.77
Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol (2007) 2.77
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71
Neurolymphomatosis. Neuro Oncol (2003) 2.68
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol (2002) 2.49
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45
Increased expression of stem cell markers in malignant melanoma. Mod Pathol (2006) 2.39
Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum (2009) 2.38
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J Invest Dermatol (2010) 2.18
Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol (2006) 2.16
Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses (2008) 2.01
Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87
Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol (2007) 1.83
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol (2011) 1.79
The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis (2013) 1.62
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol (2006) 1.57
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology (2011) 1.57
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics (2009) 1.53
The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol (2003) 1.53
Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol (2005) 1.45
Follicular malignant melanoma: a case report of a metastatic variant and review of the literature. J Am Acad Dermatol (2011) 1.39
Images in HIV/AIDS. Sweet syndrome and syphilis in an HIV-infected person. AIDS Read (2008) 1.39
HHV8 is not limited to Kaposi's sarcoma. Mod Pathol (2005) 1.38
Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol (2004) 1.29
Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol (2013) 1.28
Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg (2006) 1.24
Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J (2002) 1.24
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One (2012) 1.19
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol (2005) 1.16
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. AIDS (2009) 1.13
Rare variations in IL36RN in severe adverse drug reactions manifesting as acute generalized exanthematous pustulosis. J Invest Dermatol (2013) 1.12
Bullous pemphigoid therapy -- think globally, act locally. N Engl J Med (2002) 1.09
Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol (2011) 1.07
Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiol Drug Saf (2011) 1.04
Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS (2007) 1.03
Characterization of the biological activities of uridine diphosphate in human dendritic cells: Influence on chemotaxis and CXCL8 release. J Cell Physiol (2004) 0.99
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol (2012) 0.98
The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol (2003) 0.97
Reported use of photosensitizing medications and basal cell and squamous cell carcinoma of the skin: results of a population-based case-control study. J Invest Dermatol (2007) 0.96
Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol (2002) 0.95
Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol (2011) 0.95
Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Care Med (2009) 0.95
Lysophosphatidic acid induces chemotaxis, oxygen radical production, CD11b up-regulation, Ca2+ mobilization, and actin reorganization in human eosinophils via pertussis toxin-sensitive G proteins. J Immunol (2004) 0.93
Use of in vivo confocal microscopy in malignant melanoma: an aid in diagnosis and assessment of surgical and nonsurgical therapeutic approaches. Arch Dermatol (2004) 0.92
"Nevus/melanocytoma/melanoma": that which we call a rose by any other name would smell as sweet. Arch Pathol Lab Med (2012) 0.91
Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet J Rare Dis (2011) 0.91
C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma. Appl Immunohistochem Mol Morphol (2005) 0.88
Telaprevir: pharmacokinetics and drug interactions. Antivir Ther (2012) 0.88
Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther (2013) 0.88
Expression of neurotrophin receptor Trk-C in nevi and melanomas. J Cutan Pathol (2003) 0.87
Granulomatous and suppurative dermatitis at interferon alfa injection sites: report of 2 cases. J Am Acad Dermatol (2002) 0.87
Dermatologic changes induced by repeated Ixodes scapularis bites and implications for prevention of tick-borne infection. Vector Borne Zoonotic Dis (2009) 0.87
The influence of lysophosphatidic acid on the functions of human dendritic cells. J Immunol (2002) 0.87
Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges (2015) 0.87
Nano-biosensor development for bacterial detection during human kidney infection: use of glycoconjugate-specific antibody-bound gold NanoWire arrays (GNWA). Glycoconj J (2004) 0.86
Matrix metalloproteinases in the progression and regression of Kaposi's sarcoma. J Cutan Pathol (2006) 0.86
High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol (2005) 0.85
Tumor necrosis factor alpha induces upregulation of CXC-chemokine receptor type II expression and magnifies the proliferative activity of CXC-chemokines in human melanocytes. Eur J Dermatol (2003) 0.84
Histological characterization of regression in acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Cutan Pathol (2004) 0.84
Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother Oncol (2008) 0.83
Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics (2007) 0.82
Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus. J Cutan Pathol (2010) 0.82
Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res (2011) 0.81
Low-affinity nerve growth factor receptor (P75 NGFR) as a marker of perineural invasion in malignant melanomas. J Cutan Pathol (2009) 0.81
Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. Arch Dermatol (2007) 0.81
Impact of bar-code labeling of clinical photographs on patient care and practice workflow. Arch Dermatol (2012) 0.81
Black thyroid. Ear Nose Throat J (2003) 0.81
Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Exp Dermatol (2011) 0.81
The psychometric properties of the psoriasis disability index in United States patients. J Invest Dermatol (2005) 0.81
Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. J Clin Gastroenterol (2015) 0.80
Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol (2003) 0.80
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology (2009) 0.80
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2012) 0.80
Allergological approach to drug hypersensitivity reactions. J Dtsch Dermatol Ges (2008) 0.80
A randomized, controlled trial of four ablative fractionated lasers for photoaging: a quadrant study. Dermatol Surg (2012) 0.79
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. J Hepatol (2007) 0.79
A promising step forward in psoriasis therapy. JAMA (2003) 0.79
Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk? Drug Saf (2013) 0.79
STROBE: a Beacon for observational studies. Arch Dermatol (2008) 0.78
The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. Arch Dermatol (2009) 0.78
Topical tretinoin, another failure in the pursuit of practical chemoprevention for non-melanoma skin cancer. J Invest Dermatol (2012) 0.78
Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study. J Am Acad Dermatol (2007) 0.78
A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis. J Dtsch Dermatol Ges (2008) 0.78
Going beyond associative studies of psoriasis and cardiovascular disease. J Invest Dermatol (2012) 0.77
Cellular senescence as a possible mechanism for halting progression of keloid lesions. Genes Cancer (2011) 0.77